A study by Queen Mary University of London researchers, funded by Cancer Research UK, confirms the role of the oestrogen receptor biomarker in ductal carcinoma in situ and presents a new and more accurate method to predict long term outcomes for this pre-invasive stage of breast cancer. The study is published in Clinical Cancer Research.
Oestrogen receptor (ER), a protein expressed in some breast cancer cells, is routinely tested in invasive breast cancer to predict long-term outcomes select treatment options. Its role in ductal carcinoma in situ (DCIS) has been previously unclear, and it is not generally evaluated in this pre-invasive stage of breast cancer. The new research confirms the role of ER in predicting long-term outcomes in DCIS, and the authors report a new and more accurate method to evaluate ER for predicting long-term outcomes in DCIS.
This is the first study to use samples from a randomised trial (the UK/ANZ DCIS trial) to investigate ER as a prognostic marker in DCIS. The researchers observed multi-clonality in ER expression in 11% of ER-positive DCIS (ie: ER-positive DCIS with distinct ER-negative clones) and investigated the prognostic role of such multi-clonality in ER expression. They found that ER is a strong prognostic factor with greater than 3-fold risk of ipsilateral recurrence in ER-negative DCIS, and therefore conclude that ER should be routinely assessed in DCIS and that the clonal method they report should be considered.
Lead author Mangesh Thorat from Queen Mary University of London said: “It is unlikely that such a study could currently be reproduced elsewhere in the world, and the robustness of these results means we can rely on them to make changes to clinical practice. Routine testing of ER in DCIS will help to avoid both overtreatment and undertreatment in this type of breast cancer. The insights from this study will also help improve future breast cancer research through use of new scientific models, particularly in areas of drug resistance and the use of targeted therapies.”
Michelle Mitchell, chief executive of Cancer Research UK, said: “It’s currently very difficult to determine whether DCIS will develop into invasive breast cancer, meaning thousands of people undergo unnecessary and intense treatment. This research shows that in the future we might be able make sure patients are getting the right care, potentially saving many from undergoing cancer treatment that is both physically and mentally demanding.”
Mangesh A Thorat, Pauline M Levey, Louise J Jones, Sarah E Pinder, Nigel J Bundred, Ian S Fentiman, Jack Cuzick. Prognostic value of ER and PgR expression and the impact of multi-clonal expression for recurrence in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. Clinical Cancer Research (2021). DOI: 10.1158/1078-0432.CCR-20-4635
Queen Mary, University of London
More accurate method to predict long term outcomes for pre-invasive breast cancer (2021, March 16)
retrieved 16 March 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.